Hematology Advisor

Hematology Advisor is a no-cost online platform designed for hematology healthcare professionals. It serves as a valuable source of practical information and clinical tools to support informed decision-making for patient care. Our goal is to deliver clinical and medication information that is centered on current and upcoming best practices in hematology, aiding professionals in making the best choices for their patients.

International

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#1856514

United States

#681423

Health/Health Conditions and Concerns

#1953

Traffic sources

Monthly visitors

Articles

Reduced-Dose Apixaban Noninferior for Preventing VTE Recurrence in Patients With Cancer

2 days ago | hematologyadvisor.com | Stephan Cho

Extended anticoagulation using reduced-dose apixaban was found to be noninferior to using full-dose apixaban in preventing recurrent venous thromboembolism (VTE) in patients who had active cancer in a clinical trial, results of which were reported in the New England Journal of Medicine.
Luspatercept Shows Promise in Alleviating Anemia Associated With LR-MDS

6 days ago | hematologyadvisor.com | Ryner Lai

After 6 months of treatment, patients with lower-risk myelodysplastic syndrome (LR-MDS) who received luspatercept demonstrated greater improvement in anemia compared with patients who received erythropoiesis-stimulating agents (ESAs), according to a poster presentation at the ASCO 2025 Annual Meeting. Amanam and colleagues conducted a retrospective review of medical records of patients with LR-MDS who either received 1L of luspatercept or 1L of ESA between October and December 2024.
CAPTIVATE Long-Term Data Show Ibrutinib+Venetoclax Offers Durable PFS/OS in CLL/SLL

6 days ago | hematologyadvisor.com | Ryner Lai

Long-term follow-up data show ibrutinib (Ibr)+venetoclax (Ven) offers durable progression-free survival (PFS) and overall survival (OS) benefits to patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), including patients with high-risk genomic features, according to data presented at the ASCO 2025 Annual Meeting. Ghia and colleagues presented the final analyses of data from the phase 2 CAPTIVATE study (NCT02910583).
Study Determines Optimal Dose of Asciminib in Children With CML-CP

1 week ago | hematologyadvisor.com | Ryner Lai

Asciminib prescribed in pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) at a dose of 1.3 mg/kg BID was effective and well-tolerated, according to a poster presented at ASCO 2025 Annual Meeting. Asciminib is the first BCR::ABL1 inhibitor that works by specifically targeting the ABL Myristoyl Pocket (STAMP) and is indicated for adult patients with CMP-CL (either newly diagnosed or previously treated).
Combination Zilovertamab Vedotin and R-GemOx is Safe, Effective in R/R DLBCL, Data Suggest

1 week ago | hematologyadvisor.com | Ryner Lai

Results from a phase 2/3 study suggest that the combination of zilovertamab vedotin (ZV) with rituximab and gemcitabine-oxaliplatin (R-GemOx) is efficacious and safe in patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL), according to a presentation at the ASCO 2025 Annual Meeting.. Studies consistently show that patients with R/R DLBCL have a poor prognosis.
Sintilimab Plus ICE Improved CR Rates in Patients With cHL

1 week ago | hematologyadvisor.com | Ryner Lai

The combination of sintilimab with ifosfamide, carboplatin, and etoposide (ICE) significantly improved complete remission (CR) rates among patients with classical Hodgkin lymphoma (cHL) and had an acceptable safety profile, according to data presented at the ASCO 2025 Annual Meeting.
Intervention Reduces Acute Care Use and Costs for Older Patients With Cancer

1 week ago | hematologyadvisor.com | Erin Clancy

A symptom assessment intervention can reduce acute care use and costs for older adults with cancer, according to a study presented at the ASCO Annual Meeting 2025. The study included 416 patients who had newly diagnosed or relapsed cancer, were 75 years of age and older, and were insured by a Medicare Advantage payer partner. The patients’ median age was 82 years, and 41.4% had stage IV disease.
Light-Intensity Physical Activity Improves QOL in Patients With Cancer Regardless of Pandemic Conditions

1 week ago | hematologyadvisor.com | Ryner Lai

Physical activity of a light intensity is a key predictor of the physical function aspect of quality of life (QOL) in patients with respiratory and digestive system cancers, both during and outside the COVID-19 pandemic, according to a study published in Supportive Care in Cancer. Cancer remains one of the leading causes of death globally. The progressive nature of cancer means that QOL is slowly compromised as patients deteriorate across physical and mental domains.
Improved Patient Access to Diagnostic Testing, Appropriate Therapies Key to Improving Outcomes in Acquired AA

1 week ago | hematologyadvisor.com | Ryner Lai

There remains an urgent need for improved patient access to diagnostic evaluations and appropriate therapies in acquired aplastic anemia (AA), according to a study published in the Annals of Hematology. Anti-thymocyte globulin (ATG) is the primary treatment used to treat AA; studies have demonstrated its efficacy in improving hematopoiesis and overall survival. Because AA is so rare, the medical literature on this subject remains relatively scarce.
Some Patients With Cancer From Low-Income Countries Travel to the US for Care

2 weeks ago | hematologyadvisor.com | Jessica Nye

Some international pediatric patients with hematologic and solid malignancies engage in medical tourism to the United States (US) for treatment, according to a study published in the Journal of Clinical Oncology-Global.1 For the subset of patients from low-income countries, medical tourism can have a significant impact on outcomes.